The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sintilimab combined with bevacizumab biosimilar as a conversion therapy in potentially resectable intermediate-stage hepatocellular carcinoma (HCC): Updated results of a phase II trial.
 
Huichuan Sun
Honoraria - Bayer; BeiGene; Eisai; Innovent Biologics; Jiangsu Hengrui Pharmaceuticals; MSD; Roche; TopAlliance BioSciences Inc
 
Xiaodong Zhu
Honoraria - BeiGene; Eisai; MSD
 
Qiang Gao
No Relationships to Disclose
 
Shuang-Jian Qiu
No Relationships to Disclose
 
Ying-Hong Shi
No Relationships to Disclose
 
Xiao-Ying Wang
No Relationships to Disclose
 
Xiao-Wu Huang
No Relationships to Disclose
 
Xin-Rong Yang
No Relationships to Disclose
 
Yuan Ji
No Relationships to Disclose
 
Yanrui Pang
No Relationships to Disclose
 
Yi-Feng He
No Relationships to Disclose
 
Yong-Feng Xu
No Relationships to Disclose
 
Jie Liu
No Relationships to Disclose
 
Mingquan Sun
No Relationships to Disclose
 
Mei-Ling Li
No Relationships to Disclose
 
Jin-Jin Zhu
No Relationships to Disclose
 
Ying-Hao Shen
No Relationships to Disclose
 
Cheng Huang
No Relationships to Disclose
 
Jian Zhou
No Relationships to Disclose
 
Jia Fan
No Relationships to Disclose